Innovation in Pediatric Medical Devices: Thinking Outside The Box Gwenyth Fischer University of Minnesota Masonic Children’s Hospital.

Slides:



Advertisements
Similar presentations
Personalized Medicine in California Kathryn Lowell, Deputy Secretary for Life Sciences and Health Systems February, 2009.
Advertisements

BME-IDEA Workshop, September 28, 2005
Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
NICHOLAS FREUDENBERG,DrPH Distinguished Professor of Public Health and Faculty Co- Director, NYC Food Policy Center Six Strategies for Growing Good Food.
Rare Diseases and FDASIA
1 Confidential Science of Stem Cells and Potential Applications Andrea Hunt February 22, 2008.
Office of Orphan Products Development (OOPD) Gayatri R. Rao, M.D., J.D. Acting Director NORD Corporate Council May 15, 2012.
Senate Education Committee Briefing Russell Ingram, Executive Director March 23, 2011.
The Israel Export & International Cooperation Institute Israel’s Medical Devices and Supplies Industry Rising to the Challenge.
Medical Devices and Pediatrics Shannon Nees, PGY-2 December 9, 2013.
Advancing technology and science companies. The Neem Tree is fast-growing and can thrive even in difficult drought-like conditions. Like the rapidly growing.
Going Beyond the Current Regulatory and Incentives Frameworks A new proposal to foster greater orphan drug development 1.
NCI Designation: Expanding Science and Promoting Health in the Region Name Title, Company Date.
US Pharmaceutical/Medical Device Regulatory and Product Development Overview Tom Gardner.
DOING WHAT MATTERS FOR JOBS AND THE ECONOMY Steven Glyer, Chair – Los Angeles-Orange County Regional Consortia May 30, 2014 California Community Colleges.
IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.
Oakland University William Beaumont School of Medicine An Opportunity of a Lifetime.
January 3, 2003 Kevin Rakin President and Chief Executive Officer Kevin Rakin President and Chief Executive Officer Economic Summit and Outlook 2003.
Building a Community of Innovation and Commercialization: The BEACON Model Presentation to UConn Engineering Department April 29, 2010.
The Health Care Sector Analysts: Heather Hund and Emily Butler.
Careers in Biomedical Engineering Technology BMET 4350 Fall 2003 Dr. Hugh Blanton.
1 INVESTING IN ARIZONA’S UNIVERSITIES INVESTING IN ARIZONA’S UNIVERSITIES Presentation by The University of Arizona, May 5, 2008.
DMD Conference McNamara Alumni Center April 10, 2013 Bin He, Ph.D. Director, Institute for Engineering in Medicine.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Global Forum on Law, Justice and Development October 10,
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
Global Leadership in Medical Innovation: “Ours to Lose”
Seeking and celebrating the finest in student biomedical innovations BME IDEA Competition.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
The Economic and Societal Impact of The University of Washington (FY 08-09) Research and analysis completed by 1 July 2010.
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
Economic Mission of Israel in Singapore מדינת ישראל The State of Israel Israel Life Science Seminar April 2005 Why Israel? Anat Katz Commercial Attaché.
11-1 Copyright © 2010 Pearson Education, Inc. publishing as Prentice Hall Part IV: Start-up Financial Strategy Chapter 11: Funding the Technology Start-up.
Human Subject Research Portal Presenter Department Children's Hospital Colorado.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
LARGEST & FASTEST GROWING INDUSTRY. HOSPITALS Acute care facility Focus on critical needs of patient Average length of stay 4.8 days Classified by type.
+ Role of Industry in Clinical Care, Research, and Education.
RARE / ORPHAN DISEASES “ARE WE READY FOR THE CHANGE THAT WE NEED TO FIND EFFECTIVE TREATMENTS FOR ORPHAN DISEASE?”
Developing medicines for the future and why it is challenging Angela Milne.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
Industry Prospective Robin Bostic, Thoratec VP Health Policy and Health Economics INTERMACS Industry Sub-Committee Representative Our Future.
FDA Regulation Economically Harmful & Morally Indefensible.
23 States and D.C. have enacted medical cannabis programs1
Technology Transfer in The United States Paul Zielinski Director, Technology Partnerships Office, National Institute of Standards and Technology Chair,
Prepared by Collaborative Economics. EXECUTIVE SUMMARY  San Diego is participating in a new global innovation economy  San Diego’s global reach has.
ENGINEERINGSOLUTIONS. Horizontally and vertically integrated system 5 hospitals & 33 ambulatory care centers 20,000+ employees & 1,200 employed physicians.
Personalised Healthcare FP7 Challenge 5: ICT for Health, Aging Well, Inclusion and Governance.
Novel Approaches for Accelerating Pediatric Device Development Gwenyth Fischer, Jodi Rebuffoni, Karen Kaehler, Tucker LeBien, Sandra Wells.
Division of Cardiovascular Devices
February 2017 Demystifying Georgia Tech
OUS Data: What does the CE Mark Really Mean?
Universities and the Commercial World
REPURPOSING - SOCIAL IMPACT BONDS FOR MEDICINE
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
The FDA Early Feasibility Study Pilot and the Innovation Pathway
Human Subject Research Portal
First-in-Man, First In The USA: What’s The Difference?
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Taking Discoveries from Lab to Marketplace
Early Feasibility in the USA –An Academic View
Gestora brasileiro focada exclusivamente na área da saúde.
Human Subject Research Portal
Innovative Medicines Initiative:
Lessons Learned from the Mistakes of Others
Opening an IND: Investigator Perspective
Research, Experimentation, & Clinical Trials
Pharmaceuticals Industry
Pediatric Medical Device Market is expected to grow at a CAGR of approximately 10.5% during the forecast period PREPARED BY Market Research Future.
Pediatric Medical Device Market is expected to grow at CAGR of approximately 10.5% during the forecast period PREPARED BY Market Research Future.
Presentation transcript:

Innovation in Pediatric Medical Devices: Thinking Outside The Box Gwenyth Fischer University of Minnesota Masonic Children’s Hospital

The Pediatric Device Lag

Adult Ventricular Assist Device Pediatric Ventricular Assist Device

Adult Ventricular Assist Device

Why the Lag? Funding Testing Regulation Patient

Funding-Venture Capital Split Rock Criteria for Investment: – Significant market size “”typically greater than $500 million” – “Rapid development timeline commercialization potential in less than 5 years”

Peds versus Adult Device Market Adult Global Heart Valve market: $1.2billion Pediatric Heart Valve Market: $ million Circulation Research.2005; 97:

Testing: Smaller Test population Cia.gov

Regulation: Approval Through the FDA Traditionally more stringent requirements Testing is difficult on a pediatric population

Traditional Device Pathway The average ‘new’ device takes 100 million dollars and 10 years to get to U.S. market

Medical Device Development Plan Ideation Engineering Patent Submission Protototyping Bench Proof of Concept Animal Model Proof of Concept First in Man Clinical Trials Manufacturing Plan FDA Submission Reimbursement Plan Marketing Post Market Follow Up

Device Shrink Children are not small adults Threedonia.com

Kids are Complex Age and Size variation Growth Immune Variation Dependence on Caretakers

The Traditional Method of Making and Selling Medical Devices Doesn’t Work for Small Market Populations. So What Now?

Pediatric Device Consortia Some funded by FDA Collaboration between – University – Industry – Non-profits – Private Inventors University Industry Community

PDIC Pediatric Device Innovation Consortium at the University of Minnesota:

Humanitarian Use Fast track for Devices Designed for Populations of <4,000 per year Must prove benefit is more than risk 144 products with Humanitarian Use designation 44 Approved through Humanitarian Device Exemption

Example of Humanitarian Use-the Melody Valve Made by Medtronic First approved Transcatheter valve Congenital heart disease Humanitarian Use designation

Alternative Sources of Funding SBIR/STTR Crowdsourcing University Clinical Translational Science Institutes (CTSI) Student Engineering Projects (senior design classes)

Professional Help On the FDA Webpage Atlanta Pediatric Device Consortium – um.org/ um.org/ Michigan Pediatric Device Consortium – National Capital Consortium – New England Pediatric Consortium – Southern California Center – Philadelphia Pediatric Consortium – UCSF Peds Consortium – Other Resources PDIC Pediaworks